A U.S.-based cannabis company, Curaleaf Holdings Inc., has made a bid to acquire Aurora Cannabis Inc., an Edmonton-headquartered firm. In response, Aurora has established a special committee to review the unsolicited offer. Curaleaf plans to merge with Aurora to create a global cannabis entity operating in 17 countries across Europe, North America, and other markets.
Curaleaf, listed on the Toronto Stock Exchange, decided to publicly present its acquisition proposal after unsuccessful private negotiations with Aurora’s leadership. Despite sending formal letters outlining the bid on June 23 and July 7, Aurora’s board reportedly declined to engage in discussions. Curaleaf’s CEO expressed disappointment at Aurora’s lack of engagement and emphasized the strategic benefits of the merger.
The proposed deal entails paying Aurora shareholders $4 US per share, along with an additional $0.75 US in cash per share. Aurora confirmed receipt of the letters from Curaleaf but disputed the claim that it had refused to engage with the offer. The Canadian company stated that its lead independent director had recently communicated with Curaleaf’s CEO and affirmed its commitment to executing its business plan.
Aurora intends to form a special committee of independent directors to assess the proposal’s alignment with stakeholders’ interests. The company emphasized that the outcome is uncertain, and until a decision is reached, it will continue with its regular operations. While acknowledging Curaleaf’s interest, analysts argue that the proposed offer undervalues Aurora’s long-term potential and market leadership in the medical cannabis sector.
Curaleaf believes that merging with Aurora will leverage its global reach and Aurora’s strong international presence and production capabilities. The combined revenue of both companies exceeded $1.5 billion US in the past year, with Curaleaf anticipating annual cost synergies of at least $40 million US from the acquisition. The CEO of Curaleaf sees the merger as beneficial for both sets of shareholders and an opportunity to capitalize on evolving U.S. regulatory trends.
